We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+9.27%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$423M
AUM Growth
+$4.74M
Cap. Flow
-$21.3M
Cap. Flow %
-5.03%
Top 10 Hldgs %
48.91%
Holding
89
New
6
Increased
19
Reduced
26
Closed
5

Top Buys

Rank Stock Value
1
LXEO icon
Lexeo Therapeutics
LXEO
+$2.99M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$1.87M
3
BPMC
Blueprint Medicines
BPMC
+$1.69M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$1.2M
5
ALLO icon
Allogene Therapeutics
ALLO
+$1.19M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$7.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.27M
3
VKTX icon
Viking Therapeutics
VKTX
+$3.73M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.69M
5
TSVT
2seventy bio
TSVT
+$1.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRQR icon
51
ProQR Therapeutics
PRQR
$268M
$1.65M 0.39%
905,582
– –
CMPS
52
Compass Pathways
CMPS
$1.83B
$1.53M 0.36%
243,210
– –
GPCR icon
53
Structure Therapeutics
GPCR
$3.74B
$1.49M 0.35%
34,000
+29,000
+580% +$1.12M
IMVT icon
54
Immunovant
IMVT
$8.2B
$1.48M 0.35%
51,996
+4,080
+9% +$120K
RGLS
55
DELISTED
Regulus Therapeutics
RGLS
$1.41M 0.33%
895,200
– –
GOSS icon
56
Gossamer Bio
GOSS
$87.2M
$1.4M 0.33%
1,419,262
+10,000
+0.7% +$9.62K
LCTX icon
57
Lineage Cell Therapeutics
LCTX
$282M
$1.22M 0.29%
1,350,708
– –
MDWD icon
58
MediWound
MDWD
$184M
$1.16M 0.28%
64,479
-60,000
-48% -$1.1M
STRO icon
59
Sutro Biopharma
STRO
$400M
$1.14M 0.27%
32,958
– –
PYPD icon
60
PolyPid
PYPD
$92.2M
$1.06M 0.25%
308,497
+123,651
+67% +$444K
NYXH
61
Nyxoah
NYXH
$131M
$1.03M 0.24%
108,108
– –
BNTX icon
62
BioNTech
BNTX
$22.9B
$1.01M 0.24%
+8,500
New +$781K
ACET icon
63
Adicet Bio
ACET
$74.1M
$864K 0.2%
37,500
– –
CGEN icon
64
Compugen
CGEN
$218M
$809K 0.19%
447,202
-15,000
-3% -$27.4K
ACRV icon
65
Acrivon Therapeutics
ACRV
$72.3M
$787K 0.19%
112,414
-8,937
-7% -$70.4K
SAGE
66
DELISTED
Sage Therapeutics
SAGE
$781K 0.18%
108,200
-8,000
-7% -$73.2K
GRAL
67
GRAIL Inc
GRAL
$2.72B
$671K 0.16%
+48,800
New +$740K
ADCT icon
68
ADC Therapeutics
ADCT
$144M
$643K 0.15%
204,081
– –
BDTX icon
69
Black Diamond Therapeutics
BDTX
$110M
$544K 0.13%
+125,000
New +$680K
TRML
70
DELISTED
Tourmaline Bio
TRML
$491K 0.12%
19,110
-56,872
-75% -$949K
PHGE icon
71
BiomX
PHGE
$1.72M
$409K 0.1%
+21,112
New +$765K
MASI
72
DELISTED
Masimo
MASI
$400K 0.09%
3,000
– –
VSTM icon
73
Verastem
VSTM
$519M
$382K 0.09%
+127,700
New +$346K
APRE icon
74
Aprea Therapeutics
APRE
$7.83M
$377K 0.09%
137,174
– –
FHTX icon
75
Foghorn Therapeutics
FHTX
$327M
$351K 0.08%
37,664
-4,186
-10% -$30.3K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, DAFNA Capital Management held 89 positions worth $423M, up 1.1% from $419M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management withdrew a net $21.3M in Q3 2024, closing 5 positions and reducing 26 holdings. Its most notable exit was Morphic Holding, Inc. Common Stock, an estimated $7.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Lexeo Therapeutics worth $2.27M.

  • DAFNA Capital Management's largest Q3 2024 buy was Lexeo Therapeutics: 250,583 shares worth $2.27M.
  • DAFNA Capital Management added most to IDEAYA Biosciences in Q3 2024, an estimated $1.87M increase.
  • DAFNA Capital Management's biggest Q3 2024 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.27M.
  • DAFNA Capital Management fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $7.9M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $423M portfolio in Q3 2024.
  • DAFNA Capital Management opened 6 new positions and closed 5 in Q3 2024.
  • DAFNA Capital Management's portfolio value rose 1.1% quarter-over-quarter to $423M.

Based on DAFNA Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.